NO972868L - Oligonucleotide-dendrimer conjugates - Google Patents
Oligonucleotide-dendrimer conjugatesInfo
- Publication number
- NO972868L NO972868L NO972868A NO972868A NO972868L NO 972868 L NO972868 L NO 972868L NO 972868 A NO972868 A NO 972868A NO 972868 A NO972868 A NO 972868A NO 972868 L NO972868 L NO 972868L
- Authority
- NO
- Norway
- Prior art keywords
- dendrimer
- oligonucleotide
- natural
- modified
- nucleic acid
- Prior art date
Links
- 239000000412 dendrimer Substances 0.000 title abstract 5
- 229920000736 dendritic polymer Polymers 0.000 title abstract 5
- 108091034117 Oligonucleotide Proteins 0.000 abstract 2
- 230000000295 complement effect Effects 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 239000002773 nucleotide Substances 0.000 abstract 2
- 125000003729 nucleotide group Chemical group 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
Oligonukleotid-dendrimer konjugater, der dendrimeren er et enverdig residie av en dendrimer av første til tiende generasjon og oligonukleotidet er en naturlig, modifisert eller syntetisk sekvens som består av naturlige, modifiserte eller syntetiske deoksynukleosider eller peptidnukleinsyrebyggeblokker som er bundet via intemukleotidbroer og som omfatter en region som er komplementær, fortrinnsvis fullstendig komplementær, til en målnukleinsyre (mål-RNA eller mål-DNA), der dendrimeren er bundet til en intemukleotidbro, en nukleinsyrebase eller en sukker av nukleotidet, og saltene av disse.Oligonucleotide dendrimer conjugates, wherein the dendrimer is a monovalent residue of a first to tenth generation dendrimer and the oligonucleotide is a natural, modified or synthetic sequence consisting of natural, modified or synthetic deoxynucleosides or peptide nucleotide-linked building blocks such as which is complementary, preferably completely complementary, to a target nucleic acid (target RNA or target DNA), wherein the dendrimer is bound to an internucleotide bridge, a nucleic acid base or a sugar of the nucleotide, and its salts.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH385494 | 1994-12-21 | ||
| CH4795 | 1995-01-09 | ||
| PCT/EP1995/004933 WO1996019240A1 (en) | 1994-12-21 | 1995-12-13 | Oligonucleotide-dendrimer conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO972868D0 NO972868D0 (en) | 1997-06-20 |
| NO972868L true NO972868L (en) | 1997-08-19 |
Family
ID=25683356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO972868A NO972868L (en) | 1994-12-21 | 1997-06-20 | Oligonucleotide-dendrimer conjugates |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0790837A1 (en) |
| JP (1) | JPH10510822A (en) |
| AU (1) | AU4344696A (en) |
| CA (1) | CA2206915A1 (en) |
| HU (1) | HUT77521A (en) |
| IL (1) | IL116456A0 (en) |
| NO (1) | NO972868L (en) |
| WO (1) | WO1996019240A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
| US5744460A (en) * | 1996-03-07 | 1998-04-28 | Novartis Corporation | Combination for treatment of proliferative diseases |
| JP2001501975A (en) * | 1997-05-28 | 2001-02-13 | ペーター・エー・ニールセン | Binding peptide nucleic acids with enhanced cellular uptake |
| GB9718129D0 (en) | 1997-08-27 | 1997-10-29 | Isis Innovation | Branched structures |
| US6287765B1 (en) * | 1998-05-20 | 2001-09-11 | Molecular Machines, Inc. | Methods for detecting and identifying single molecules |
| FR2906532B1 (en) | 2006-09-28 | 2008-12-12 | Biomerieux Sa | NEW OLIGONUCLEOTIDE BRAND |
| FR2933410B1 (en) | 2008-07-04 | 2010-08-20 | Biomerieux Sa | NEW DETECTION PROBE |
| TWI852977B (en) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | Prostate neoantigens and their uses |
| US12018289B2 (en) | 2019-11-18 | 2024-06-25 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
| CN112898580B (en) * | 2019-12-03 | 2022-11-08 | 安序源生物科技(深圳)有限公司 | Sequencing reagent |
| CN112898575B (en) * | 2019-12-03 | 2022-10-21 | 深圳清华大学研究院 | Preparation method of crotch-like macromolecule modified nucleotide |
| WO2022009051A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | A method for determining responsiveness to prostate cancer treatment |
| EP4175664A2 (en) | 2020-07-06 | 2023-05-10 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022009049A1 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE89743T1 (en) * | 1986-08-18 | 1993-06-15 | Dow Chemical Co | CONJUGATE POETS STARS. |
| IL107715A0 (en) * | 1992-11-25 | 1994-02-27 | Baxter Int | Water soluble non-immunogenic polyamide cross-linking agents |
| ES2211882T3 (en) * | 1993-07-14 | 2004-07-16 | The Regents Of The University Of California | AUTOMOTIVE POLINUCLEOTIDE ASSIGNMENT SYSTEM THAT INCLUDES DENDRIMEROS POLICATIONS. |
| MX9504664A (en) * | 1994-03-07 | 1997-05-31 | Dow Chemical Co | CONJUGATES OF BIOACTIVE AND / OR DIRECTED DENDRIMEROS. |
| IT1270994B (en) * | 1994-03-18 | 1997-05-26 | Bracco Spa | POLYOXYKYLIC STRUCTURE MACROMOLECULES WITH THEIR USE |
-
1995
- 1995-12-13 JP JP8519486A patent/JPH10510822A/en active Pending
- 1995-12-13 CA CA002206915A patent/CA2206915A1/en not_active Abandoned
- 1995-12-13 WO PCT/EP1995/004933 patent/WO1996019240A1/en not_active Ceased
- 1995-12-13 HU HU9702164A patent/HUT77521A/en unknown
- 1995-12-13 EP EP95942147A patent/EP0790837A1/en not_active Withdrawn
- 1995-12-13 AU AU43446/96A patent/AU4344696A/en not_active Abandoned
- 1995-12-19 IL IL11645695A patent/IL116456A0/en unknown
-
1997
- 1997-06-20 NO NO972868A patent/NO972868L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO972868D0 (en) | 1997-06-20 |
| IL116456A0 (en) | 1996-03-31 |
| HUT77521A (en) | 1998-05-28 |
| CA2206915A1 (en) | 1996-06-27 |
| AU4344696A (en) | 1996-07-10 |
| WO1996019240A1 (en) | 1996-06-27 |
| JPH10510822A (en) | 1998-10-20 |
| EP0790837A1 (en) | 1997-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO972868L (en) | Oligonucleotide-dendrimer conjugates | |
| DK51092D0 (en) | OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF | |
| ATE373671T1 (en) | AMINOOXY-MODIFIED OLIGONUCLEOTIDES | |
| ATE239090T1 (en) | METHOD FOR GENERATING SINGLE STRANDED DNA MOLECULES | |
| DK0698105T3 (en) | Nucleotide sequences to control the expression of DNA sequences in a host cell | |
| BR9813968A (en) | Nucleic acid molecules that encode proteins having fructosyl transferase activity and processes to produce long chain inulin | |
| EA200100365A1 (en) | SYNTHESIS | |
| DE69834056D1 (en) | DE NOVO OR "UNIVERSAL" SEQUENCING ARRAY | |
| ATE420192T1 (en) | METHOD FOR REDUCING THE ANTIGENITY OF THE ADENO-ASSOCIATED VIRUS STRUCTURAL PROTEIN | |
| DE69534855D1 (en) | ENZYMMETIVE DNA MOLECULES | |
| DK0408295T3 (en) | Methods for amplifying nucleic acid sequences | |
| WO1998039485A3 (en) | Compositions and methods for analysis of nucleic acids | |
| DK0973928T3 (en) | DNA-based transposon system for introducing nucleic acid into DNA in a cell | |
| DE69403642D1 (en) | 7-DEAZAPURIN MODIFIED OLIGONUCLEOTIDES | |
| DE69431485D1 (en) | DOUBLE-STRANDED PEPTIDE NUCLEIC ACIDS | |
| DE69524740D1 (en) | Thymidine kinase MUTANT | |
| CY1109797T1 (en) | NUCLEAR ACID Molecules, Coding Enzymes That Have Fructosyl Transfer Activity, and Their Use | |
| BR9500271A (en) | Vector DNA sequence, plasmid, cell, protein, mutant process for the isolation of nucleic acids. Process for the preparation of sugars and use | |
| ATE87932T1 (en) | ALPHA OLIGONUCLEOTIDES. | |
| DK0840802T3 (en) | Method of Sequencing through Oligomer Hybridization | |
| DE69815370D1 (en) | FLUORESCEND CONJUGATES OF NUCLEOSIDES AND NUCLEOTIDES, THEIR METHOD FOR THE PRODUCTION AND THEIR USE | |
| SE9403805D0 (en) | Method of preparing oligonucleotide probes or primers, vector therefor and use thereof | |
| ATE317123T1 (en) | REACTIVE CARRIER FOR DETERMINING DNA FRAGMENTS | |
| ATE408621T1 (en) | DNA MOLECULES | |
| EP0985045B1 (en) | Modulators of morphogen expression and methods of identifying the same |